Compare BRN & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRN | PHGE |
|---|---|---|
| Founded | 1956 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2M | 6.9M |
| IPO Year | N/A | N/A |
| Metric | BRN | PHGE |
|---|---|---|
| Price | $1.09 | $2.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $26.00 |
| AVG Volume (30 Days) | 45.2K | ★ 124.8K |
| Earning Date | 12-17-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $18,073,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.05 | $2.28 |
| 52 Week High | $2.28 | $22.06 |
| Indicator | BRN | PHGE |
|---|---|---|
| Relative Strength Index (RSI) | 42.09 | 48.79 |
| Support Level | $1.05 | $2.31 |
| Resistance Level | $1.16 | $2.85 |
| Average True Range (ATR) | 0.05 | 0.59 |
| MACD | -0.01 | -0.22 |
| Stochastic Oscillator | 13.64 | 35.00 |
Barnwell Industries Inc is an oil and gas firm. Its areas of operations include acquiring, developing, producing, and selling oil and natural gas. The company acquires and develops crude oil and natural gas assets. The company's operating segment includes Oil and natural gas, Contract drilling, Land investment, and Others. It generates maximum revenue from the Oil and natural gas segment. It operates in two geographical segments the United States, which generates a majority of revenue, and Canada.
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).